Clinical Trials
10 trialsNCT03631199 2026-02-25
CANOPY-1
Novartis
Phase 3 Terminated
NCT03742349 2025-05-18
Study of Safety and Efficacy of Novel Immunotherapy Combinations in Patients With Triple Negative Breast Cancer (TNBC).
Novartis
Phase 1 Terminated
NCT03447769 2024-10-09
Canopy-A
Novartis
Phase 3 Terminated
NCT03968419 2024-06-20
CANOPY-N
Novartis
Phase 2 Terminated
NCT03484923 2024-06-18
PLATforM
Novartis
Phase 2 Completed
NCT03626545 2023-08-21
CANOPY-2
Novartis
Phase 3 Terminated
NCT03064854 2022-08-15
PDR001 in Combination With Platinum-doublet Chemotherapy and Other Immunology Agents in PD-L1 Unselected, Metastatic NSCLC Patients
Novartis
Phase 1 Terminated
NCT02900664 2022-03-29
A Study of PDR001 in Combination With CJM112, EGF816, IlarisĀ® (Canakinumab) or MekinistĀ® (Trametinib)
Novartis
Phase 1 Completed
NCT02334748 2020-05-19
A Study of Canakinumab in Patients With Systemic Juvenile Idiopathic Arthritis or Hereditary Periodic Fevers Who Participated in the CACZ885G2301E1, CACZ885G2306 or CACZ885N2301 Studies
Novartis
Phase 3 Completed
NCT02911857 2018-08-20
An Extention Study of Safety of Canakinumab in Japanese Patients With Periodic Fever Syndromes
Novartis
Phase 3 Completed